AmericasENPublic drug registration overview
Brazil Pharmaceutical Registration Pathway
Market Overview Market profile: Brazil is Latin America's largest pharmaceutical market. SUS procurement, private channels, local manufacturing preference, and Portuguese complianc...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.
AI Citation Summary
- Country: Brazil Pharmaceutical Registration Pathway
- Product line: Pharmaceuticals
- Regulator / source: Regulatory maturity: High. ANVISA regulates clinical trials, APIs, medicines, biologics, marketing authorisation, and post-approval changes.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Market profile: Brazil is Latin America's largest pharmaceutical market. SUS procurement, private channels, local manufacturing preference, and Portuguese compliance strongly shape entry.
- Regulatory maturity: High. ANVISA regulates clinical trials, APIs, medicines, biologics, marketing authorisation, and post-approval changes.
- Core decision: Classify the product as new drug, generic, similar medicine, biologic, OTC, herbal, radiopharmaceutical, or another category before filing.
Regulator
- Authority: ANVISA, Agência Nacional de Vigilância Sanitária
- Official portal: https://www.gov.br/anvisa/en/regulation-of-products/drugs
Product Types and Review Pathways
| Type | Pathway focus |
|---|---|
| New drug | Full quality, nonclinical, clinical, and benefit-risk data |
| Generic | Reference medicine, BE, quality, and Portuguese labeling |
| Similar medicine | Branded generic route requiring equivalence evidence |
| Biologic | Comparability, clinical evidence, GMP, and batch control |
Registration Pathway
During the limited-time free period, sign in or register to view the complete pharmaceutical country report.